ACHIEVE Pilot Statins for Vascular Protection
ACHIEVE
A Cluster-randomized Trial to Improve Use of High IntEnsity Statins for Vascular Protection
2 other identifiers
observational
225
1 country
2
Brief Summary
ACHIEVE aims to increase statin usage among patients with ASCVD by having a pharmacist talk to patients and providers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2025
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2024
CompletedFirst Posted
Study publicly available on registry
August 13, 2024
CompletedStudy Start
First participant enrolled
May 19, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2026
CompletedAugust 7, 2025
August 1, 2025
2 months
August 5, 2024
August 6, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Provider engagement as measured by recruitment
The goal is recruiting at least 25% of identified providers.
2 years
Patient engagement as measured by recruitment
The goal is to recruit at least 30% of identified patients overall and within the black population
2 years
Study Arms (1)
No statin
Patients who are identified with ASCVD who do not take a statin or do not take the recommended dose.
Interventions
Pharmacists will call patients and their providers to discuss benefits of statin use
Eligibility Criteria
The study population includes patients who have an ASCVD diagnosis but are currently not treated with a moderate-high intensity statin.
You may qualify if:
- Patients with a diagnosis of atherosclerotic cardiovascular disease currently not treated with a moderate- high intensity statin and the providers that care for them.
- Patient age 18-75
You may not qualify if:
- Hemodialysis
- History of rhabdomyolysis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Duke Universitylead
- Carelon Researchcollaborator
- Harvard Pilgrim Health Carecollaborator
- National Heart, Lung, and Blood Institute (NHLBI)collaborator
Study Sites (2)
Carelon Research
Wilmington, Delaware, 19801, United States
Duke Clinical Research Institute
Durham, North Carolina, 27701, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher Granger, MD
Duke University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 5, 2024
First Posted
August 13, 2024
Study Start
May 19, 2025
Primary Completion
July 31, 2025
Study Completion
February 28, 2026
Last Updated
August 7, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Data will be shared after publication of the final manuscript and will continue until the data from the main study is available for sharing.
- Access Criteria
- Unrestricted access will be provided to parties who sign a standard data sharing agreement.
We will provide requested unrestricted data to parties who sign a data sharing agreement which stipulates that data must be: 1) used solely for research purposes, 2) properly acknowledged in resulting publications, 3) kept confidential and inaccessible to third parties, and 4) destroyed or returned after analyses are completed. Additionally, users must agree not to use data to identify individual participants. Letters of agreement will be executed so that research materials can be provided to not-for-profit institutions. The study team further agrees that all resource sharing agreements comply with the Bayh-Dole Act of 1980 and the Technology Transfer Commercialization Act of 2000. We will not be using model organisms.